Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026

Century Therapeutics, Inc.

De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.
Reduces headcount by ~25%; closes labs in Seattle and Hamilton, consolidates research in Philadelphia.
Extends cash runway into 2026; Phase 1 CNTY-101 enrollment expected imminently; partnered BMS programs unaffected.
Hy Levitsky, President of R&D, resigns effective Jan 31, 2023; Luis Borges and Adrienne Farid assume responsibilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.